Deselex

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deselex

Quick Facts

Property Description
Active ingredient Desloratadine
Forms Tablet, Oral Solution, Syrup
Pharmacological class Antihistamine (H₁-receptor antagonist)
Common purpose Relief of allergic symptoms
Origin Synthetic (Active metabolite of Loratadine)

What is Deselex? Defining the Drug's Identity and Class

Deselex is a pharmaceutical product whose active substance is desloratadine, a synthetic tricyclic antihistamine. It is formally classified as a second-generation selective H₁-receptor antagonist, targeting the mechanisms that cause allergic symptoms. Desloratadine is recognized as the major active metabolite of the older medication loratadine, which is a key distinguishing factor, as the compound is readily available in its active form upon oral route administration, differentiating it from medications that require extensive initial metabolism. This non-sedating classification is clinically recognized for its long duration of action, offering reliable symptomatic control. This means the medicine is less likely to cause common side effects like drowsiness than older antihistamines.

Composition and Available Forms of Desloratadine

The formulation of Deselex is a single-ingredient product, containing only desloratadine as the sole pharmacologically active substance, combined with necessary inactive base materials. This medication is administered via the oral route and is available in various high-level dosage forms, including conventional tablets, film-coated tablets, specialized orally disintegrating tablets (ODT), and liquid preparations such as syrup or oral solution. The availability of liquid forms is specifically important for accommodating patient groups such as children who require a liquid base instead of a solid form.

The General Purpose of Deselex

The primary general purpose of Deselex is to provide anti-allergic activity by controlling the body’s adverse reaction to allergens. It achieves this through selective peripheral H₁-receptor antagonism, which serves to suppress the biological effects of the chemical mediator histamine. By blocking the action of histamine at key receptors, the drug is designed to alleviate the common physical signs associated with allergic conditions, such as reducing pruritus (itching), suppressing the formation of urticaria (hives), and controlling the symptoms associated with allergic rhinitis. A typical neutral use scenario involves taking the medication to relieve seasonal nasal congestion and itchy eyes caused by pollen exposure.

Regulatory References

  1. NIH DailyMed: Desloratadine Label
  2. MedlinePlus: Desloratadine

What side effects are possible with Deselex?

Possible Side Effects and Safety Information

The safety profile of Deselex (desloratadine) is formally documented according to regulatory standards, classifying adverse reactions by frequency and the physiological systems affected. Based on clinical trials in adults and adolescents (aged 12 years and older), the officially designated Common side effects (ge 1/100 to <1/10) are headache, fatigue, and dry mouth.


Documented Adverse Reactions

Adverse effects reported outside of initial trials, generally categorized as Very Rare (post-marketing reports) or of Not Known frequency, involve several System-Organ Classes. These include Nervous System effects (e.g., dizziness, somnolence, seizures), Gastrointestinal Disorders (e.g., nausea, diarrhea), and effects on the Hepatobiliary System (e.g., hepatitis, elevated liver enzymes).

Serious adverse reactions documented in official labeling, although rare, include severe hypersensitivity reactions (such as anaphylaxis and angioedema) and Cardiac Disorders such as QT prolongation and arrhythmia.


Population-Specific Safety Considerations

The medicine's regulatory profile includes specific notes for certain patient populations. Caution is advised for individuals with severe hepatic impairment or severe renal insufficiency due to the potential for increased exposure to desloratadine. In the pediatric population, specific caution is noted regarding seizure risk in children with a personal or family history of seizures. Furthermore, the tablet form carries a safety restriction for patients with rare hereditary issues like galactose intolerance.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes officially documented descriptions and mandated actions in the event of an overdose, as stated in government regulatory documents like the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).


Documented Overdose Profile

The primary presentation of Deselex (desloratadine) overdose is generally documented as a profile similar to that seen with therapeutic doses, with the official note that the magnitude of the effects can be higher. The specific symptom reported in this context is somnolence (drowsiness). High-dose clinical studies, involving up to nine times the recommended daily dose, reported no prolongation of the QTc interval and no clinically relevant effects beyond the increased magnitude of typical adverse events. For the paediatric population, the event profile is similarly documented, but the potential for higher effect magnitude is explicitly noted.


Required Emergency Actions

Immediate medical attention must be sought for severe manifestations of overdose, as stated in government health guidance, including collapse, seizure, trouble breathing, or inability to be awakened. The official regulatory management approach is defined by the need for symptomatic and supportive treatment and the consideration of standard measures to remove unabsorbed active substance. It is officially documented that desloratadine is not eliminated by haemodialysis.

Therapeutic Uses of Deselex

Main Uses of Deselex

Deselex contains desloratadine, an antihistamine used primarily to manage symptoms associated with allergic reactions. It is formulated to provide relief from both seasonal and year-round environmental triggers without causing significant drowsiness in most individuals.

Allergic Rhinitis

Deselex is used to treat the symptoms of allergic rhinitis, which include:

  • Nasal symptoms: Sneezing, runny nose, and itchy nose.
  • Ocular symptoms: Itchy, red, or watery eyes.
  • Palatal symptoms: Itching of the roof of the mouth.

The medication is effective for both seasonal allergic rhinitis (commonly known as hay fever) and perennial allergic rhinitis, which is triggered by indoor allergens such as dust mites, mold, or pet dander.

Urticaria (Hives)

In addition to respiratory allergies, Deselex is indicated for the treatment of urticaria, a skin condition characterized by itchy red bumps or wheals. It helps to:

  • Reduce the number and size of hives.
  • Alleviate the intense itching associated with skin eruptions.

Benefits and Mechanism

Non-Sedating Profile

As a second-generation antihistamine, desloratadine is designed to be highly selective for peripheral H1-receptors. This selectivity means it does not readily cross the blood-brain barrier, which allows for the relief of allergy symptoms while minimizing the sedative effects often associated with older antihistamines.

Extended Duration of Action

Deselex is characterized by a long half-life, which typically allows for a consistent effect over a 24-hour period. This long-acting nature helps maintain symptom control throughout the day and night with a single application, supporting better sleep quality and daily productivity by reducing the continuous burden of allergic symptoms.

Regulatory References

  1. DailyMed (NIH) Official Labeling for Desloratadine

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Deselex

The eligibility profile for Deselex (desloratadine) is formally established by regulatory bodies and governs use based on patient demographics and health conditions.


Classification Population/Condition
Contraindicated Patients with known hypersensitivity to desloratadine, any excipients, or the parent drug loratadine (FDA, EMA).
Established Use Adults and Adolescents (12 years and older) and Pediatric patients (as young as 6 months for specific liquid forms and indications) (FDA, EMA).
Restricted Use Patients with severe renal or hepatic impairment are identified as requiring caution and regulatory-recommended dosage adjustment (FDA, EMA).
Conditional Use Patients with a history of seizures should be administered the medicine with caution (EMA).
Formulation Restriction Use of certain tablets is restricted in patients with hereditary sugar intolerances (lactose) or Phenylketonuria (aspartame-containing ODTs).
Physiological Status Pregnancy use is preferable to avoid as a precautionary measure; use during lactation requires a decision to discontinue breastfeeding (EMA).

The regulatory documents establish eligibility by defining absolute exclusions (contraindications), setting clear age thresholds for established use, and identifying specific patient populations who require caution due to underlying organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for desloratadine documents pharmacokinetic interactions that alter the drug's systemic exposure. Co-administration studies have established that several medicinal products can increase the concentration of desloratadine and its active metabolite in the plasma.

This effect is observed with medicines including the antifungal Ketoconazole, macrolide antibiotics like Erythromycin and Azithromycin, the H₂-receptor antagonist Cimetidine, and the SSRI Fluoxetine. Despite these increases in systemic exposure, regulatory trials reported that the co-administration did not result in clinically relevant adverse events or changes to the product’s safety profile. No specific drug-drug combination is formally classified as contraindicated due to an interaction risk.

The drug's interaction profile also details specific non-interaction findings. Official studies confirm that consumption of food, grapefruit juice, or alcohol does not affect the drug’s absorption or bioavailability, nor does alcohol potentiate performance impairment.

A key consideration in the interaction profile is the potential for population-specific exposure alterations. Systemic desloratadine exposure is significantly increased in individuals with hepatic impairment (up to 2.4-fold higher AUC) and severe renal impairment due to reduced clearance. Similar increases in exposure are officially noted in subjects identified as slow metabolizers.

Mechanism of Action

How Deselex Works

Desloratadine's mechanism is defined by two primary, interconnected domains that modulate physiological pathways at the peripheral level.

Key 1: Inverse Agonism at Peripheral H1 -Receptors

The molecule's core action is functioning as an inverse agonist at the Histamine H1 -receptor. This interaction actively shifts the receptor toward an inactive state, counteracting the effects of released histamine and eliminating the receptor’s intrinsic constitutive signaling activity. The molecular action involves rapid engagement of the H1 -receptor and is concentrated outside the central nervous system due to minimal Blood-Brain Barrier (BBB) penetration, which fundamentally determines the localized, peripheral nature of the mechanism.

Key 2: Modulation of Vascular Permeability and Inflammatory Pathways

By preventing H1 -receptor activation on blood vessel walls and sensory nerves, the drug halts the cascade that leads to increased capillary permeability and localized vasodilation. This contributes to the modulation of fluid movement across the capillary endothelium and interruption of signals on sensory nerves associated with H1 -receptor activation. Furthermore, the molecule modulates underlying inflammatory signaling pathways (like NF-kappa B) and inhibits the release of various proinflammatory mediators, contributing to the overall physiological modulation.

Dosage and Administration Information

Administration Guidelines and Dosing Regimens

Deselex, with the active substance desloratadine, is exclusively administered via the oral route in its approved formulations: tablets, orally disintegrating tablets (ODT), and oral solution/syrup. The dosing schedule is standardized to once daily for all approved populations, though the specific dose strength varies based on age.

Population Standard Once-Daily Dose
Adults and Adolescents (12 years and older) 5 mg
Children 6 to 11 years 2.5 mg
Children 1 to 5 years 1.25 mg
Infants 6 to 11 months 1 mg

Use Conditions and Special Populations

The medication may be taken without regard to meals, offering flexibility in its daily timing. The total duration of use depends on the pattern of symptoms: for intermittent allergic rhinitis (symptoms present for less than four days per week or four continuous weeks), use may be discontinued when symptoms resolve. For persistent conditions, continuous treatment may be necessary.

Specific modifications to the standard regimen are required for certain adult patients. For adults with severe renal or hepatic impairment, the official guidance specifies that the dose of 5 mg should be administered every other day to account for altered drug clearance.

Administration Specifics

To ensure proper dosing, the oral solution must be measured using a calibrated measuring device instead of a household spoon. Orally disintegrating tablets (ODT) are designed to be removed from the blister pack (by peeling back the foil) and placed on the tongue to dissolve and be swallowed immediately, with or without water. If a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Deselex

Research Evidence for Allergic Rhinitis (Hay Fever)

The official research base for desloratadine, which has been studied for symptoms in allergic rhinitis, involves numerous short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, typically lasting between two and four weeks. The studies were applied in trials assessing short-term or episodic symptom patterns and frequently compared the use of desloratadine against a placebo. These trials included Adults and Adolescents as well as separate studies on Pediatric populations.

In these trials, researchers primarily monitored patient-reported outcomes describing perceived discomfort. The main study outcomes were related to physical discomfort, specifically measuring changes in combined scores for nasal symptoms (like sneezing, runny nose, and itching) and ocular symptoms (like watery eyes). The research highlights changes measured during the short study period. Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to change in the composite symptom scores.

Research Evidence for Chronic Hives (Chronic Idiopathic Urticaria)

Research examining Chronic Idiopathic Urticaria (CIU), or chronic hives, relies heavily on short-to-intermediate-term Randomized Controlled Trials. The studies focused on research contexts involving fluctuating or unstable symptoms, as this is a condition characterized by fluctuating or episodic manifestations. The research was applied in studies examining patient-reported experiences in those with chronic hives.

In these studies, researchers monitored outcomes related to physical discomfort. They used standardized tools, such as the Urticaria Activity Score (UAS), to track key symptoms. Studies monitored changes in the reported severity of pruritus (itching) and the number and size of wheals (hives). The findings describe patterns observed in the studies related to change in the activity level of the condition over the study duration, which was typically up to six weeks.

Evaluation of Treatment Duration and Long-Term Follow-up

Most of the primary regulatory evidence used in research exploring short-term symptom changes was observed in trials lasting only a few weeks (four to six weeks at most). Long-term effects are not fully established. Evidence is limited for maintenance patterns beyond short-term use. Research examining chronic hives indicates that long-term effects are not fully established, and evidence regarding the recurrence rate of the condition after treatment is stopped remains insufficient.

Studies in Specific Patient Groups

Desloratadine was evaluated in studies designed for specific patient groups beyond the general adult population. For allergic rhinitis, dedicated research examined the patterns of change measured during the study period in Pediatric populations, including children as young as 2 years of age. In addition, the compound was studied for allergic rhinitis in patients presenting with certain comorbid conditions, specifically mild asthma. However, data for other specific groups, such as the elderly, remain insufficient.

Key Limitations and Evidence Gaps

The available research base highlights what is known and what is still uncertain about desloratadine. The primary research limitation frames is that the follow-up durations were limited in many of the key efficacy trials. The research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted, and data show patterns related to symptom changes measured only during the short study periods. The certainty remains low for the persistence of observed patterns over extended periods.

Frequently Asked Questions (FAQ)

Common questions about Deselex (FAQ)

Q: Does Deselex help with both depression and anxiety?

According to the official product information, Deselex is approved for the treatment of Major Depressive Disorder (MDD). The regulatory documents do not specify a sole indication for anxiety. Studies and official information focus on its established effectiveness in treating depression.

Q: Can I take Deselex if I am pregnant or breastfeeding?

Regulatory documents state that Deselex should generally be avoided during pregnancy and breastfeeding. The use of this medicine during these periods may pose risks to the developing baby. Regulatory sources advise patients to consult a healthcare professional regarding use during these specific periods.

Q: Is it safe to drive or operate machinery while taking Deselex?

Official product information indicates that Deselex may cause side effects such as dizziness or drowsiness, which could impair your ability to drive or operate heavy machinery. Official guidance suggests caution and monitoring personal effects before engaging in activities that require significant focus.

Q: Can Deselex be taken with or without food?

According to regulatory sources, Deselex tablets can be taken either with a meal or without food. There is no requirement in the official documentation to take it only at specific times relative to eating. The most important factor is adhering to the prescribed schedule, regardless of food timing.

Q: Is Deselex a controlled substance?

Studies and official information indicate that Deselex is a prescription-only medicine (POM) in most regions, meaning it must be dispensed by a pharmacist with a valid prescription. However, it is not typically categorized as a federally controlled substance under major international drug regulations.

Q: How long does it takes for Deselex to start working?

Regulatory documents state that the full benefit of Deselex may take several weeks of consistent use to become noticeable. While some patients may report early changes, patients are generally advised to continue the treatment course as prescribed because improvement typically happens gradually.

Q: What is the risk of withdrawal symptoms when stopping Deselex?

Official product information mentions that abruptly stopping Deselex can lead to discontinuation symptoms, which may include dizziness, nausea, and headache. The official documentation emphasizes that the prescribed way to stop treatment is by gradually reducing the dose under medical supervision.

Q: Can Deselex be crushed or split?

According to official product information, Deselex is designed to be swallowed whole. There is no instruction in the regulatory documents permitting the tablet to be crushed or split. Alteration of the tablet is not recommended, as it could potentially change the medicine’s intended release into the body.

How should Deselex be stored and disposed of?

How to Store and Dispose of Deselex (Desloratadine)

Official regulatory documents define specific, mandatory conditions for storing and disposing of Deselex to maintain product stability and safety.

Storage Requirements

Formulation Temperature Requirement Handling/Protection Rule
Tablets Store at or below 25 °C (77 °F) Protect from moisture
Syrup/Oral Solution Store at or below 30 °C (86 °F) Do not freeze

Both the tablets and the syrup must be stored in their original container and must be kept out of the sight and reach of children, as required by all official labeling.

Disposal Requirements

Unused or expired Deselex should be disposed of according to local requirements or regulations. Official guidance specifies that the medicine must not be thrown away via wastewater or household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deselex found in:

A-Z Index: